Non‐segmental vitiligo and psoriasis comorbidity – a case‐control study in Italian patients. (26th February 2013)

• Record Type: Journal Article
• Authors: Arunachalam, M.; Dragoni, F.; Colucci, R.; Berti, S.; Crocetti, E.; Galeone, M.; Conti, R.; Moretti, S.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 28:Number 4(2014:Apr.)
• Page Start: 433
• Page End: 437
• Publication Date: 2013-02-26
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.12117
• Languages: English
• ISSNs: 0926-9959

Abstract

<abstract abstract-type="main" xml:lang="en" id="jdv12117-abs-0001"> <title>Abstract</title> <sec id="jdv12117-sec-0001" sec-type="section"> <title>Background</title> <p>A recent systematic evaluation of vitiligo and psoriasis comorbidity has not yet been reported in a large series of patients with vitiligo.</p> </sec> <sec id="jdv12117-sec-0002" sec-type="section"> <title>Objective</title> <p>To investigate the practical/clinical implications in subjects with both vitiligo and psoriasis compared to those with vitiligo alone.</p> </sec> <sec id="jdv12117-sec-0003" sec-type="section"> <title>Methods</title> <p>This was a case‐control study on 463 vitiligo patients in our clinic from March 2008 to April 2011. Medical assessment was performed by dermatologists using the modified Vitiligo European Task Force form.</p> </sec> <sec id="jdv12117-sec-0004" sec-type="section"> <title>Results</title> <p>In an univariate analysis, inflammation/pruritus [odds ratio (OR) 2.42, <italic>P</italic> = 0.03], use of drugs that can induce psoriasis (OR 2.74, <italic>P</italic> = 0.01), a family history (FH) of psoriasis (OR 2.87, <italic>P</italic> = 0.02), cardiovascular disease (OR 5.70, <italic>P</italic> = 0.001), hypertension (OR 4.7, <italic>P</italic> = 0.006) and type 2 diabetes mellitus (OR 3.87, <italic>P</italic> = 0.004), were significantly correlated with patients exhibiting vitiligo and psoriasis comorbidity. A trend was found in personal history of cardiovascular disease in patients with both diseases (OR 2.99, <italic>P</italic> = 0.07). FH of vitiligo was significantly associated with patients having only vitiligo (OR 0.35, <italic>P</italic> = 0.05). Multivariate analysis demonstrated that inflammation/pruritus in vitiligo macules (OR 2.56, <italic>P</italic> = 0.047) and a FH of cardiovascular disease (OR 4.07, <italic>P</italic> = 0.02) were the most significant predictors of patients having both psoriasis and vitiligo, while the presence of organ‐specific autoantibodies (OR 0.24, <italic>P</italic> = 0.007) was significantly associated with patients having only vitiligo.</p> </sec> <sec id="jdv12117-sec-0005" sec-type="section"> <title>Conclusion</title> <p>The presence of vitiligo and even mild psoriasis is significantly correlated with a family history of cardiovascular disease, a factor that requires greater attention and follow‐up with respect to that necessary for vitiligo patients.</p> </sec> </abstract>